Tag: M.W:300-400

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1119-97-7,MitMAB,as a common compound, the synthetic route is as follows.

General procedure: A 100mL round-bottom flask was equipped with a magnetic stir bar and a reflux condenser. To xylene (10.0mL), tetradecyltrimethylammonium bromide (1.1mmol) and a heterocyclic compound (1.0mmol) were added, followed bya solution of NaOH 50% (5.0 mL). The mixture was stirred at reflux temperature for 2-18 h. After completion of thereaction, the mixture was air-jet cooled to 25 C and TLC indicated the disappearance of the starting material. The reaction mix was treated with AcOEt (4 ¡Á 20 mL), and the organic phase separated and removed under reduced pressure. The residue was purified to analytical purity by column chromatography., 1119-97-7

1119-97-7 MitMAB 14250, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Gonzalez-Gonzalez, Carlos A.; Vega, Juan Javier Mejia; Monroy, Ricardo Garcia; Gonzalez-Calderon, Davir; Corona-Becerril, David; Fuentes-Benites, Aydee; Mascarua, Joaquin Tamariz; Gonzalez-Romero, Carlos; Journal of Chemistry; vol. 2017; (2017);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

448-61-3, 2,4,6-Triphenylpyrylium tetrafluoroborate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a suspension of the corresponding amine (2.0 mmol) and 2,4,6-triphenylpyrylium tetrafluoroborate (2.0 mmol) in EtOH (20 mL) in a round bottle flask was added Et3N (2.0 mmol). The mixture turned deep-brown while the educts dissolved and was stirred for 30 min at rt followed by the addition of AcOH (4.0 mmol) and heating under reflux conditions for additional 2 h. The product precipitated during the reaction. The product was dissolved directly in the flask with little acetone at the reflux temperature after the reaction was finished (no further precipitate occurred). After cooling down to rt the product crystallized as a yellow solid, which was filtered off, washed with cold EtOH and pentane and dried in vacuo., 448-61-3

The synthetic route of 448-61-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Menzel, Roberto; Kupfer, Stephan; Mede, Ralf; Goerls, Helmar; Gonzalez, Leticia; Beckert, Rainer; Tetrahedron; vol. 69; 5; (2013); p. 1489 – 1498;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a solution of (25,5 ?)-6- (benzyloxy)-7-oxo-N-[2-(2H-l,2,3-triazol-2-yl)ethoxy]-l,6-diazabicyclo[3.2.1]octane-2- carboxamide (4 g, 10.3 mmol, upper spot as per thin layer chromatography in Step 3) in dimethylformamide (20 ml) and dichloromethane (20 ml) was added palladium over carbon (10%, 1.0 g) under nitrogen atmosphere. The reaction mixture was flushed with hydrogen gas and stirred for 3 hour under hydrogen pressure (55 psi). The progress of reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (9: 1) as solvent system. After complete conversion, the reaction mixture was filtered through celite bed and washed with a mixture of dichloromethane and dimethylformamide (20 ml, 1: 1). The collected filtrate was evaporated under reduced pressure to dryness. The intermediate thus obtained was dissolved into dimethylformamide (20 ml) and dimethylformamide sulfur trioxide complex (2.4 g, 15.6 mmol) was added under stirring at 0 C. The reaction mixture was allowed to attain ambient temperature and stirred further for 1 hour. The completion of reaction was monitored by performing thin layer chromatography using mixture of chloroform and methanol as solvent system. After complete conversion, the reaction mixture was cooled to 0C and then a solution of tetra butyl ammonium acetate (5 g, 16.5 mmol) in water (17 ml) was slowly added under stirring. After 1 hour, the reaction mixture was concentrated to dryness in vacuum and co-evaporated with xylene (2×30 ml) to dimethylformamide free mass. To this concentrated mass, water (40 ml) was added and then extraction with dichloromethane was carried (2×40 ml). The collective organic layer was dried on anhydrous sodium sulfate and concentrated to dryness to provide 8.5 g of crude compound. It was purified using column chromatography (silcagel 60- 120) by using mixture of dichloromethane and methanol as an eluent. The pure compound was isolated at 5% concentration of methanol in dichloromethane; the collective fractions were collected and evaporated to obtain 3.5 g of tetrabutyl ammonium salt of (25,5 ?)-7-oxo-6-(sulfooxy)-N-[2-(2H- l,2,3-triazol-2-yl)ethoxy]- l,6-diazabicyclo[3.2.1]octane- 2-carboxamide in 55% yield. Analysis: Mass: 375.2 (M- l, for free acid) for Molecular weight: 617 and Molecular formula: C27H5iN707S., 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; DOND, Bharat; PATEL, Mahesh Vithalbhai; (100 pag.)WO2017/81615; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The chloro-bridged dimeric iridium complex[Ir(ppz)2Cl]2 (123 mg, 0.12 mmol) and 4,7-diphenyl-1,10-phenanthroline (88 mg, 0.26 mmol) were dissolved in CH2Cl2 (15 ml) and MeOH (15 ml). The mixture was refluxed under nitrogen for 12 h and the yellow solution obtained was cooled to room temperature and solid ammonium tetrafluoroborate (52 mg, 0.5 mmol) was added to it. The reaction mixture was stirred at room temperature for 1 h and the solvent was evaporated under vacuum. The product obtained was dissolved in dichloromethane, filtered to remove the unwanted inorganic impurities, and then precipitated with hexane. The crude material obtained was purified by column chromatography (Merck Alox 90; CH2Cl2 changing toCH2Cl2/MeOH, 100:2) yielding the desired product as yellow solid (156 mg, 0.17 mmol,73%). The chemical structure of the cationic iridium complex is shown in Fig. 1. 1H NMR(500 MHz, CD2Cl2) delta (ppm): 8.50 (d, J = 5.2 Hz, 2H), 8.13 (d, J = 3.1 Hz, 2H), 7.66 (d, J = 5.1 Hz, 2H), 7.61-7.54 (m, 4H), 7.33 (d, J = 7.1 Hz, 2H), 7.26 (d, J = 2.93 Hz, 2H),7.11-7.07 (m, 4H), 6.98-6.92 (m, 4H), 6.54 (t, 5.1 Hz, 1H), 6.48-6.46 (m, 1H). 13C NMR(126 MHz, CD2Cl2) delta (ppm): 151.6, 150.8, 148.3, 143.5, 139.0, 135.8, 130.3, 129.9, 129.7,129.4, 127.2, 126.9, 126.5, 123.6, 121.7, 111.7, 108.7. Anal. Found (%): C 56.25, H 3.45,N 9.34. Anal. Calcd for C42H30N6BF4Ir: C 56.19, H 3.37, N 9.36., 1662-01-7

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sunesh, Chozhidakath Damodharan; Chandran, Midhun; Ok, Sunseong; Choe, Youngson; Molecular Crystals and Liquid Crystals; vol. 584; 1; (2013); p. 131 – 138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,56-54-2

Phenylacetic acid (40 mg, 0.294 mmol)and quinidine (95.4 mg, 0.294 mmol) were dissolved in acetone.Crystals were obtained after 3 days. Similar crystals were obtained using ethyl methyl ketone, tetrahydrofuran, isopropanol, ethanol and methanol as solvents.

The synthetic route of 56-54-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Amombo Noa, Francoise M.; Jacobs, Ayesha; Journal of Molecular Structure; vol. 1114; (2016); p. 30 – 37;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1866-16-6,S-Butyrylthiocholine iodide,as a common compound, the synthetic route is as follows.

General procedure: The method was adapted for measurement of very low cholinesterase activity in samples, high throughput screening and serial assays. Thus, measurements on enzyme samples of 10 mul were performed either in a Peltier thermostated spectrofluorimeter F-7100 (Hitachi Ltd.,Japan) using standard spectrofluorimetic cuvettes of 1 cm-path length in a total volume of 1.5 ml, or in a titration microplate reader (TecanInfinite F Plex) using a total volume of 200 mul per well (96-well titration plate, 7.5mm well ?). Stock solutions of substrates were 100mM ATC or BTC prepared inwater. These solutions were stored at -20 C. Because of thioester unstability, only freshly thawed solutions were used. Final substrate concentrations ranged between 2 and 1000 muM. Stock solution of Probe IV was 1mM made in DMSO and stored at -20 C. The solution is light sensitive. The final concentration of Probe IV in current assays was 10 muM. During the time-course of assays for determination of ChE activity, the fluorescence stops increasing when 1% of substrate is consumed, i.e. 10 muM thiocholine released. Thus, under steady-state conditions, [S] is almost constant and remains much larger than the enzyme concentration, i.e. >0.798mM for [S0]=800 muM. Then, the initial rate is linear until consumption of all probe. The final DMSO concentration in assay was 1% v/v. Though DMSO is known as a reversible ChE inhibitor (e.g. for human AChE,IC50=2.6% v/v in the presence of 1mM ATC), the inhibitory effect of 1% DMSO was considered as weak. The current volume of pure enzymes per assay was 15 mul in spectrofluorimetric cuvette and 10 mul per plate reader well. However, assays were also performed with sample volumes ranging from 5 to 30 mul. The final concentration in active sites per assay was as low as 10-12 M. For most kinetic studies, the active site concentration was 1.3¡Á10-10 M for BChE, 2.5¡Á10-11M for AChE, 3¡Á10-9M for BChE mutant E197Q and 1.5¡Á10-9M for mutant E197G. Measurements of activity were performed at the optimum pH of both enzymes and 25 C, the standard temperature for kinetic and thermodynamic studies. The rate of hydrolysis of ATC or BTC wasmonitored in 0.1M sodium phosphate buffer pH 8 for AChE and pH 7 for wild-type and mutants of BChE at 25 C for 3 min in spectrofluorimeter and for 2 min in microplate reader by the fluorescence emission of Probe IV-thiocholine conjugate (Scheme 2) (DeltaIF/dt) withlambdaex=400 nm and lambdaem =465 nm. On Hitachi spectrofluorimeter, lambdaex slit was 5.0 nm and lambdaem slit 10.0 nm. The Tecan titration plate readerwas equipped with light filters with bandwith of lambdaex ¡À 35 nm andlambdaem ¡À 35 nm. The fluorescence background of Probe IV was substracted. In addition, owing to the spontaneous hydrolysis of ATC and BTC, the fluorescence background due to spontaneous substrate hydrolysis was substracted for each concentration. Assays of human plasma BChE in a total volume of 2 ml were performed using 0.8mM BTC in 0.1M sodium phosphate buffer at 25 C. 1to 100 mul of plasma samples were taken for measurements using the classical Ellman’s method. For determination of BChE activity using the Probe IV method, plasma was diluted 100 or 1000 times in 0.1M phosphate buffer pH 7.0, and 1-100 mul samples of diluted plasma wereassayed in spectrofluorimeter. For both methods, reaction rates were recorded for 2 min., 1866-16-6

As the paragraph descriping shows that 1866-16-6 is playing an increasingly important role.

Reference£º
Article; Mukhametgalieva, Aliya R.; Zueva, Irina V.; Aglyamova, Aliya R.; Lushchekina, Sofya V.; Masson, Patrick; Biochimica et Biophysica Acta – Proteins and Proteomics; vol. 1868; 1; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a stirred solution of 2,4 dimethoxy benzaldehyde (0.542 g, 3.3 mmol) in tetrahydrofuran (10 ml.), was added N, N-diisopropyl ethyl amine (1.0 g, 7.0 mmol) followed by the addition of (25,5 ?)-N-(2-hydrazino-2-oxoethyl)-7-oxo-6-(sulfooxy)- l,6-diazabicyclo [3.2.1 ]octane-2- carboxamide (1 g, 3.0mmol) at 25C. The reaction mixture was stirred for 16 hours and to the resulting mixture was added a solution of tetrabutylammonium acetate (0.3 g, 3.0 mmol) in tetrahydrofuran (10 ml.) and stirring continued further for 24 hours. The solvent was evaporated under reduced pressure and the residue was taken up in dichloro methane (20 ml) and washed with 10% aqueous potassium hydrogen sulfate solution (3 ml x 2) and finally organic layer was washed with water (5 ml). The organic layer was separated and dried over anhydrous sodium sulfate and evaporated under reduced pressure to yield a semi solid residue. This was purified by column chromatography over silica-gel (60- 120 mesh) by eluting with mixture of methanol in dichloro methane (5: 95). The combined fractions were evaporated under reduced pressure to obtain 1.1 g of tetrabutylammonium salt of (25,5 ?)-N-{2-[(2E,Z)-2-(2,4-dimethoxybenzylidenehydrazino]-2-oxoethyl}-7-oxo-6-(sulfooxy)- l,6- diazabicyclo[3.2.1]octane-2-carboxamide as a white solid in 51%

10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar Jagdishwar; TADIPARTHI, Ravikumar; LOGANANTHAN, Velupillai; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; PAWAR, Mangesh; PATEL, Piyush Ambalal; JOSHI, Prashant Ratnakar; PATEL, Mahesh Vithalbhai; (57 pag.)WO2017/2089; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1119-97-7, MitMAB is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1119-97-7, General procedure: Aqueous NBTA3- solution is obtained by dissolving NBTA (33.4mg, 0.075mmol) into 150mL twice distilled water. Later, 3 eqvi. NaOH (9mg, 0.225mmol) is added to the aqueous solution. After sealing, the sample is stirred at 60C for 8h to ensure completely soluble. The concentration of NBTA3- solution is calculated as 5¡Á10-5M. Then, dissolving different quaternary ammonium salts into NBTA3- solution. After stirring for 30minat room temperature (25C), NBTA3-/ammonium salts solution become transparent, which then is subjected to further instruments analysis.

1119-97-7 MitMAB 14250, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Ma; Yang; Cao; Lei; Lei; Dyes and Pigments; vol. 140; (2017); p. 131 – 140;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1119-97-7,MitMAB,as a common compound, the synthetic route is as follows.

General procedure: In a typical synthesis of DA-La(PW11)2, an aqueous solution of (2.0 g, 0.31 mmol) K-La(PW11)2 was dropped into a chloroform solution of (1.1 g, 3.75 mmol) DA-Br. A white precipitate formed after the addition of the whole K-La(PW11)2 aqueous solution and then the product was separated after a further 1 h of stirring. The product was washed twice with H2O and dried in air [9]. DDA-La(PW11)2, TDA-La(PW11)2, HDA-La(PW11)2 and ODA-La(PW11)2 were prepared with a similar procedure. In the 1H NMR spectra, the singlet peak at 2.5 ppm and 3.3 ppm is assigned to be DMSO-d6, and the water in DMSO-d6, respectively.

1119-97-7, As the paragraph descriping shows that 1119-97-7 is playing an increasingly important role.

Reference£º
Article; Zhao, Shen; Jia, Yueqing; Song, Yu-Fei; Applied Catalysis A: General; vol. 453; (2013); p. 188 – 194;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

144222-34-4, N-((1R,2R)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[0219] To a solution of the enone (450 mg, 1 mmol, 1.0 equiv) in 0.5 M/4.5 mL/g anhydrous PhCH3 or dichloromethane (DCM) under N2 atmosphere was added Et3N (0.14 mL, 1 mmol, 1.0 equiv) and HCO2H (0.05 mL, 1.2 mmol, 1.2 equiv) at room temperature (RT). The resulting solution was stirred for 10 min and then treated with solid (R,R)-(-)-Ru-TsDPEN-cymene complex1 (19 mg, 0.03 mmol, 0.03 equiv) all at once. The reaction mixture was then aged at RT for 2 h, at which a complete consumption of starting material was observed. Tert-butyl methyl ether-MTBE (5 mL) was added followed by 1N HCl (2 mL). The organic layer was separated, washed with saturated Na2CO3, brine, dried over MgSO4, filtered and concentrated in vacuo to give the final compound as viscous oil. [0220] The catalyst can also be generated in situ by mixing 0.02 mol equiv of [RuCl2(p-cymene)2] and 0.04 mol equiv of the (R,R)-N-Tosyl-1,2-diphenylethylene-1,2-diamine in DCM (dichloromethane) in the presence of 0.04 mol equiv of 1M solution KOtBu in THF (tetrahydrofuran). After aging for 10 min at RT, Et3N was added followed by HCO2H and a solution of the enone in DCM). [0221] The catalyst was prepared by mixing 1 mol equiv of [RuCl2(p-cymene)2], 2 mol equiv (R,R)-N-Tosyl-1,2-diphenylethylene-1,2-diamine and 4.2 mol equiv of Et3N in iPrOH at 80 C. for 1 h (hour). After solvent removal, the solid was washed with cold H2O and the recrystallized from MeOH to give the catalyst as orange solid., 144222-34-4

144222-34-4 N-((1R,2R)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide 2734565, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-Claire; Young, Robert N.; US2004/198701; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI